Long-Term Tetrahydrobiopterin Treatment in PKU Patients of 0-18 Years - Study on Phenylalanine Tolerance and Safety

NCT00432822 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Phenylalanine Hydroxylase Deficiencies

Interventions

DRUG: tetrahydrobiopterin (BH4)

Sponsor

Orphanetics Pharma Entwicklungs GmbH